US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
Germany’s Merck has linked with Array BioPharma and Pierre Fabre to initiate a lage-stage trial assessing the efficacy of a new combination therapy in BRAF-mutant metastatic colorectal cancer.